The approach applies deep learning and could potentially be used to identify people with early-stage disease when therapies may have more of an effect.
The company said that it is on track to meet its goal of shaving $7.2 million in costs this year as it undertakes a recently announced restructuring plan.
Fresh off a name change, the company last week introduced a monitoring platform for new SARS-CoV-2 variants that alerts diagnostic test makers to potential problems.
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
Investigators identified natural killer cell-related expression signatures in blood samples from children who later developed type 1 diabetes or islet autoimmunity.
The study's finding suggest that over-stimulation of the complement pathway along with non-specific targeting of lung tissue contribute to death from the virus.
The companies will integrate their respective technologies into a platform for clinical genetics services, including test ordering and virtual counseling.
More than a dozen countries issue a statement expressing concerns about the World Health Organization report on the origins of the COVID-19 pandemic, Reuters reports.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
